Maria Arantxa Horga

📢 Introducing one of our many #PanelDiscussions during the 2 day #PDDPSUMMIT at the Hilton Boston Park Plaza Email us at [email protected] to learn more! #DrugDiscovery #Preclinical #Antibodies #DrugDevelopment #AI #ML #MedTech #Biopharma #Pharma #Biotech #SmallMolecules #Biologics #LifeScienes #Medicine #Scientists #LifeScience #LargeMolecules

8

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a clinical stage #biopharmaceutical company focused on developing new #antibiotics for difficult-to-treat #bacterial infections, has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for August 9, 2024, at 8:00 am ET, before the U.S. financial markets open.   The company's President and CEO, David Luci, along with CFO Robert Shawah, will host the call to present the #financial results and provide a business update. #Investors and interested parties can join the call using the provided toll-free number for U.S. participants or international access numbers.   https://lnkd.in/esMuCywW #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci

14

I want to remind everyone about the upcoming 2024 Philly Cell & Gene Therapy Conference. Don't miss the "Talk-To-An-Investor" session on June 15th from 2:40 PM to 4:45 PM at the Sheraton Valley Forge Hotel.   This is a fantastic opportunity to engage in 15-minute discussions with esteemed investors if you’re looking for RNA/ASO Tx angled funding.   💡My Session Highlights - June 15th: 1️⃣ Bioanalytical Strategies for In Vivo Quantification of Nucleic Acid Therapy 2️⃣ Delivery Challenges of Oligo Nucleotide Therapy 3️⃣ Model-Informed Drug Development for Nucleic Acid Therapy   At Rockland Immunochemicals, Inc., we're making significant advancements with our ModDetect™ panels. These panels are designed to facilitate the detection of specific chemical modifications independent of the sequence or location of the modification and can be used to evaluate a variety of RNA Tx modalities and nucleic acid structures. We’re collaborating with institutions to continue driving innovation in nucleic acid therapeutics. I would be happy to discuss opportunities with you and help connect you with the right people at the conference.   Looking forward to seeing you there!   #PhillyCGT #CellAndGeneTherapy #RNAtherapy #NucleicAcidTherapy #Biotech #Investors #RocklandImmunochemicals

33

BIO is a great place to network and to extend you team's capabilities. Facet Life Sciences specializes in getting smaller companies to and through FDA. If you're a small company looking to bring a new therapy or diagnostic to patients, catch up with me either 4 or 5 June. Let's spend a little time talking about what #toandthroughFDA can mean for you. #FDA #biointernational2024 #lifesciences

5

Allogene Therapeutics' Zachary J Roberts MD PhD explains the elements of #allogeneic #cartcelltherapy that make it an attractive strategy to target relapsed/refractory Chronic lymphocytic leukemia (#CLL) that could also suggest promise in additional scenarios. #cellandgenetherapy #cartcell #cgt 🔗 https://lnkd.in/eYSQAu6M

37

Alia Therapeutics is present at ASGCT Baltimore, the 27th Annual Meeting of American Society of Gene & Cell Therapy.  Meet Antonio Casini, Alia co-founder and CTO, on Wednesday 8th, presenting poster “ A novel mutation-independent CRISPR-based gene therapy to treat autosomal dominant retinitis pigmentosa”. https://lnkd.in/drdhej43 , POSTER SESSION B6 - Ophthalmic and Auditory Diseases 654   Alia Therapeutics has a vision to revolutionize medicine by curing genetic diseases at their roots. Our thesis: The diversity and complexity of human genetic diseases demands a customized approach and relying on a limited set of enzymes wouldn’t suffice. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomics sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which is required for therapeutic applications. Learn more at https://lnkd.in/dDVgwXVE #genetherapy, #geneediting, #asgct, #baltimore, #aliatherapeutics

34

Gene therapy continues to show promise in the fight against neurodegenerative diseases... In a major step forward, MeiraGTx has released promising results from its Phase 2 trial of gene therapy for Parkinson's disease, demonstrating improved motor function and quality of life for patients. The trial, conducted in collaboration with Johnson & Johnson’s Janssen Inc., marks a significant advancement in the potential of gene therapies to address unmet medical needs. These breakthroughs are not just transforming treatments but also expanding opportunities for innovation and growth. Check out the full story to see how these pioneering efforts are shaping the future of healthcare... #Biotech #GeneTherapy #VC #Innovation #Parkinsons #Healthcare #MeiraGTx #Janssen The Janssen Pharmaceutical Companies of Johnson & Johnson Zandy Forbes Samuel Waksal David A. Rubinstein, PhD, MBA Elliot Barnathan

5

1 Comment

#ICYMI our Chief Executive Officer Jeb Keiper talked with Endpoints News about HPK1, a differentiated next-generation #immunotherapy target for advanced solid tumors. Read the article here: https://lnkd.in/e-KAkZ4z

99

1 Comment